Earth's Crust Is Hiding Vast Reserves of Hydrogen – Here's How We Can Find It
Now researchers have come up with a recipe for naturally forming hydrogen, which could help locate the vast reserves of the gas that are locked away in Earth's crust.
Tapping into these reserves, the researchers say, could meet our hydrogen energy needs for up to 170,000 years. It would mean we no longer have to use hydrocarbons to produce hydrogen – which contributes to carbon dioxide emissions.
The new recipe was put together by a team from the UK and Canada. The cooking time, they estimate, is around a billion years.
"We have successfully developed an exploration strategy for helium and a similar first principles approach can be taken for hydrogen," says geoscientist Jon Gluyas, from Durham University in the UK.
Hydrogen forms in Earth's crust as water interacts with rocks that are either rich in iron or contain radioactive elements. Certain other criteria must be met too, in terms of temperature, pressure, timing, and containment.
By considering all these factors and mapping where they are present on Earth, the researchers came to the conclusion that there could be plenty of hydrogen waiting to be tapped into – as there is at the Bourakebougou site in Mali, for example.
The next problem is finding it. The recipe put together in this study lists the ingredients that experts can look for – and they all need to be included for hydrogen to be found. The research also acts like a treasure map of sorts, pointing to regions where conditions are favorable for hydrogen formation.
"We know for example that underground microbes readily feast on hydrogen," says earth scientist Barbara Sherwood Lollar, from the University of Toronto.
"Avoiding environments that bring them into contact with the hydrogen is important in preserving hydrogen in economic accumulations."
Many other researchers are also busy with this task. A study published earlier this year suggested there could be extensive hydrogen reserves locked away in the world's mountain ranges, created by the push and pull of tectonic plates.
Hydrogen is crucial today, particularly in fertilizer production to help feed the world. Demand for the gas is expected to surge, from 90 million metric tons (99 million US tons) in 2022 to 540 million metric tons by 2050. While there are artificial ways of creating hydrogen, they're expensive and not carbon neutral.
There's still a lot of work to do to locate and extract natural hydrogen – and it's going to be a finite resource when we do find it – but research like this suggests it's a viable option for a future with cleaner energy.
"One successful exploration recipe that is repeatable will unlock a commercially competitive, low-carbon hydrogen source that would significantly contribute to the energy transition," says geochemist Chris Ballentine, from the University of Oxford.
The research has been published in Nature Reviews Earth & Environment.
Piles of Penguin Poop Could Surprisingly Help Cool Antarctica
'Forever Chemicals' Found in Popular US Beers, Above EPA Limits
NOAA Forecasts a Busy Hurricane Season For 2025. What's Fueling It?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
43 minutes ago
- Business Upturn
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
By GlobeNewswire Published on August 13, 2025, 05:30 IST Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now? HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders? The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders? The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market Outlook As automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities: Drug Screening Market Carrier Screening Market Cell based Assays Market Label Free Detection Market Life Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Bloomberg
5 hours ago
- Bloomberg
Other Nations Move Toward Making Their Own Vaccines as US Cuts Funding
At least a dozen countries are interested in developing their own vaccines because they're losing confidence that the US government will have immunizations ready for the next pandemic, a top biotech investor said. Other nations have largely depended on the US to make shots that are deployed globally. The Covid-19 vaccines, developed by Pfizer Inc. and Moderna Inc. and embraced by the US government, were used by tens of millions of people around the world.
Yahoo
9 hours ago
- Yahoo
World's ‘oldest baby': what a 30-year-old embryo tells us about the future of fertility
A baby born in the US has made headlines for a surprising reason: they came from an embryo that had been frozen for more than 30 years — setting a new world record. The embryo was created and stored in 1994, back when Bill Clinton was US president and the internet, email and mobile phones were still in their infancy. Now, decades later, that embryo has become a living child. But how is this possible – and what does it mean for the future of fertility treatment? Freezing embryos is a common and effective part of in vitro fertilisation (IVF). During IVF, multiple eggs are fertilised, and any unused embryos can be frozen and stored for future use. Globally, thousands of embryos are placed in long-term storage each year – and as the demand for fertility treatment grows, so too does the number of embryos in storage. But once a person or couple finishes treatment, the question of what to do with unused embryos can become complicated. As this case in the US illustrates, families and circumstances change. Relationships may end. People may change their minds. And yet, many feel conflicted about allowing embryos to 'perish' (the term used when frozen embryos are removed from storage, thawed and not used), especially after investing significant emotional, physical and financial resources in their creation. As a result, many continue to pay storage fees for years – sometimes decades – after their treatment has ended. Embryo donation One option for those with unused embryos is to donate them. Typically, this is coordinated through the fertility clinic. But in this record-breaking case, the embryos were donated through a US Christian organisation called Snowflakes, which allows donors to choose the recipients. The donor – now a woman in her 60s – wanted a say in where the embryos went because any resulting children would be full genetic siblings to her 30-year-old daughter. In many countries, donor-conceived people are now entitled to information about their donors. But rarely does this involve embryos frozen for decades – raising the possibility of a future connection between the child, their parents and the donor family, including a half-sibling born 30 years earlier. In the US, there's no legal limit on how long embryos (or sperm and eggs) can be stored. In the UK, the maximum storage limit was recently extended to 55 years, enabling a similar situation: someone could be conceived from an embryo stored for decades, and the donor may be elderly – or even deceased – by the time contact is made. Read more: What remains unclear is how these wide age gaps between donor and child – or between donor-conceived siblings – might affect how people relate to one another. It's an area that remains largely unexplored. Finding genetic relatives As direct-to-consumer DNA testing becomes increasingly common, more donor-conceived people are turning to services like 23andMe and to find genetic relatives outside of regulated routes. These commercial tests allow users to upload a sample and receive a list of people they may be related to, including potential donors or donor siblings. With longer embryo storage periods possible, it's likely that people will use these platforms to make contact with genetic relatives across many years, bypassing formal donor registries and regulated systems. In this US case, the embryo donation took place within the same country. But that's not always the case. With the globalisation of fertility treatment, including international travel and the cross-border shipment of frozen sperm, eggs and embryos, it's increasingly common for people who are genetically related to live in different countries. A 2024 Netflix documentary about sperm donation highlighted this issue, showing how a single donor fathered children in multiple countries, prompting calls for better regulation of international donor limits. One of the most intriguing – and underexplored – questions is how people born from decades-old embryos will come to understand their origins. While research on donor-conceived families suggests that they typically function well, the idea of being 'frozen in time' for 30 years is unique. It introduces a temporal disconnect between conception and birth that may feel uncanny or dislocating. Donor-conceived people are often curious about their genetic background – but being born from an embryo created before the internet or mobile phones adds another layer to this. It could influence how people make sense of their identity, family connections, and even their place in history, especially if their genetic siblings or donors are decades older, or deceased. The long gap between fertilisation and birth raises profound questions not just about biology, but about belonging, narrative, and what it means to be from a particular time. With rapid advances in reproductive technology, it's likely this won't be the last record-breaking case. As techniques improve and cultural boundaries around family and parenthood continue to evolve, we'll see more questions arise: about identity, genetics and what it really means to be part of a family. This article is republished from The Conversation under a Creative Commons license. Read the original article. Nicky Hudson receives funding from the UK Economic and Social Research Council. She is a member of the UK NICE Guideline Committee on fertility treatment, a working group member for the Nuffield Council on Bioethics' project on Reviewing the 14-day rule, a member of the British Fertility Society's Law, Policy and Ethics group and an advisory board member for the Fertility Alliance.
